If you live in NYC & have Long Covid—reach out to our clinical team now at CoreResearch@MountSinai.org to apply.
25.02.2026 21:38
👍 4
🔁 2
💬 1
📌 0
If you live in NYC & have Long Covid—reach out to our clinical team now at CoreResearch@MountSinai.org to apply.
Interested in low-dose Rapamycin for Long Covid? The Cohen Center for Recovery from Complex Chronic Illness is actively recruiting for a RCT of the mTOR inhibitor Sirolimus (Rapamycin). The trial aims to evaluate if changes to the immune response as a result of the drug improve Long Covid symptoms.
2/ which may build up in patients’ bodies as a result of SARS-CoV-2 or Borrelia burgdorferi. If you’re interested in participating in this trial, email CoreResearch@MountSinai.org.
1/ Long Covid, ME/CFS and Post-Treatment Lyme patients living in NYC: Mount Sinai’s CoRE clinic is actively recruiting for a clinical trial of Lumbrokinase. This enzyme breaks down fibrin, a coagulation factor linked to chronic symptoms,
This work is expanding how we think about Alzheimer’s disease, which is increasingly tied to the activity of pathogens that can infect the CNS. PolyBio is excited to be growing our program on infectious contributions to Alzheimer’s in 2026. (2/2)
PolyBio scientific advisory board member Dr. William Eimer led the recent discovery of beta-amyloid & tau proteins’ antimicrobial activity targeting Herpes Simplex Virus 1 in the brain. (1/2)
The meeting highlighted NK-cell activating therapies—namely, Bioshield—which is undergoing investigation in two clinical trials for potential treatment efficacy in Long Covid.
A key theme of the discussion centred around the long-term health implications of SARS-CoV-2 viral persistence, such as immune exhaustion.
PolyBio CEO Dr. Amy Proal & PolyBio-supported researchers Timothy Henrich MD & Steven Deeks MD recently presented data on Long Covid tissue findings at the inaugural USA-Saudi Biotech Alliance summit.
polybio.org/polybio-scie...
If you have been diagnosed with Long Covid & live in NYC, consider joining this first-of-a-kind trial. Email CoreResearch@MountSinai.org to see if you’re eligible.
Want first access to antiviral therapies for Long Covid? We’re looking for participants for a clinical trial of Truvada & Maraviroc. The trial is using cutting-edge biological markers including deep immune profiling & EndoPAT to determine efficacy of these medications in LC.
We’re also ecstatic about this mAb trial—hopefully we can fast-track some effective LC treatments via the help of the SPEAR working group.
8 “may provide an extremely promising route to stopping and perhaps reversing some of that damage. We as a group are thrilled to take this next step with Invivyd."
7/ “Chronic exposure to SARS-CoV- 2 spike protein in any form may be driving ongoing morbidity in America, and we believe the monoclonal antibodies discovered and developed by Invivyd…
6/ "The SPEAR Study Group and Invivyd have longstanding interest in clinical disease that can follow COVID infection and COVID vaccination,” said PolyBio CEO and SPEAR founding member Dr. Amy Proal.
5/ The SPEAR working group, including core members of PolyBio Dr. Amy Proal, Or. David Putrino, Dr. Akiko Iwasaki, and Dr. Michael Peluso, has been crucial for the trial's design.
4/ The trial will focus on patients with Long
COVID who demonstrate evidence of chronic infection or antigen persistence in a variety of tissues, and COVID vaccine-injured people, including those who have demonstrated persistence of vaccine-delivered spike protein.
3/ VYD2311 may improve patient access to clinically significant mAb titres, due to its potential to be received intramuscularly.
2/ The novel monoclonal has demonstrated in vitro antiviral activity across all clinically recorded variants of SARS-CoV-2 tested since the original Wuhan strain, across many months of therapy.
BREAKING: PolyBio Core Team Collaborating with Invivyd for Trial of the mAb VYD2311, Launching mid-2026
This week, Invivyd announced the upcoming launch of a new randomized, double-blind clinical trial of the monoclonal antibody WYD2311 in people with Long Covid and COVID vaccine injury.
Watch Dr. Mirabent’s full presentation here, from the PolyBio Fall 2025 Symposium: youtu.be/dGbb7UDcoHw?...
2. Features of SARS-CoV-2-specific T cell responses. This includes identification of SCV2-specific T cells harboring public T cell receptors, and analysis of their clonal expansion histories.
Full project methodology: polybio.org/projects/sar...
1. The extent and nature of SARS-CoV-2 persistence in different mucosal tissue compartments, the transcriptomes and proteomes of infected cells, and the global inflammatory state of surrounding cells.
PolyBio is supporting this extension to the LIINC collaborative to collect gut tissue and FRT biopsy samples from pre-menopausal women with and without Long Covid. Advanced technologies are analyzing the samples to determine: (cont. below)
Their initial findings suggested SCV2 RNA and proteins can persist in the endometrium, endo-cervix and ecto-cervix; with more patient biopsies currently underway.
“We found evidence of SARS-CoV-2 infected cells both in the gut and female reproductive tract… more than 4 years after the initial infection,” said Dr. Marta Mirabent, who is part of the Roan lab team investigating SCV2 persistence in these sites as driver of Long Covid.
Reflecting on 2025, PolyBio helped lead the fight against Long Covid. We supported 6 clinical trials, started the Long Covid cure initiative, and began charting the route towards validated biomarkers. We’re looking forward to continuing to drive innovation for IACIs in 2026.
Thank you to everyone who supported our work this year including donors, patients, and healthy controls in our trials.
#polybio2026countdown
To wrap-up our countdown to 2026, we’re highlighting PolyBio’s key contribution to the UCSF LIINC Anktiva trial for Long Covid. The funding will allow advanced testing of patient samples to track changes in SARS-CoV-2 persistence over time.
